This site is intended for health professionals only

Nigel Gaymond appointed new CEO of BioIndustry Association

teaser

The BioIndustry Association (BIA) is pleased to announce that is has appointed Nigel Gaymond as its new Chief Executive Officer.

The new CEO, who is currently President of Gaymond International, has worked in a range of roles in the international life sciences sector for over 20 years. He will be joining the BIA in January 2010.

Following a period in sales and marketing at IBM in the UK, Nigel moved to the British Consulate-General in Boston where he ran the Commercial Department in assisting the UK’s biotechnology, healthcare and agriculture exports. Gaymond International was established after Nigel left the Consulate, in order to provide consultancy services to a range of life sciences companies in the USA and Europe. He has also worked at the healthcare and technology development company Mosaigen and the corporate and transaction adviser Tranziger. Nigel has a BSc in Linguistic and International Studies from the University of Surrey, and a post-graduate degree in Education.

Welcoming Nigel to the BIA, Chairman Dr Clive Dix said:

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
Advertisement

“We are delighted that someone of Nigel’s calibre and breadth of expertise is joining the BIA as its new CEO. His international experience with universities, government, development agencies, investment bodies and diverse companies will enable us to continue to represent the whole of the UK bioscience sector as we build on successes of this year such as the creation of the Office for Life Sciences.”

The BIA’s new CEO, Nigel Gaymond, added:

“As the UK’s leading biotechnology trade association, the BIA has built an excellent reputation for the quality of its public affairs activity, member representation and range of events. I am very much looking forward to working with BIA members, its Board and management team in expanding the organisation’s outreach to the life science sector, both domestically and globally, and in engaging with government and the finance community.”

BIA






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x